Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Design, synthesis, and biological evaluation of 1-methyl-1H-pyrazolo[4,3-b]pyridine derivatives as novel small-molecule inhibitors targeting the PD-1/PD-L1 interaction
Xinyan Dai, Ke Wang, Hao Chen, et al.
Bioorganic Chemistry (2021) Vol. 114, pp. 105034-105034
Closed Access | Times Cited: 19

Showing 19 citing articles:

Small Molecule Agents Targeting PD-1 Checkpoint Pathway for Cancer Immunotherapy: Mechanisms of Action and Other Considerations for Their Advanced Development
Pottayil G. Sasikumar, Murali Ramachandra
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 43
Anti-PD-L1-Based Bispecific Antibodies Targeting Co-Inhibitory and Co-Stimulatory Molecules for Cancer Immunotherapy
Qiaohong Geng, Peifu Jiao
Molecules (2024) Vol. 29, Iss. 2, pp. 454-454
Open Access | Times Cited: 6
Small-molecule modulators of tumor immune microenvironment
Jing Zhang, Jia Yu, Meijing Liu, et al.
Bioorganic Chemistry (2024) Vol. 145, pp. 107251-107251
Closed Access | Times Cited: 5
A computational chemistry-based approach to optimizing PD-1/PD-L1 inhibitors
Meijuan Zhai, Shiliang Ji, Haoran Hu, et al.
Frontiers in Chemistry (2025) Vol. 12
Open Access
Advancements in drug discovery: integrating CADD tools and drug repurposing for PD-1/PD-L1 axis inhibition
Patrícia Sobral, T. Carvalho, Shiva Izadi, et al.
RSC Advances (2025) Vol. 15, Iss. 4, pp. 2298-2316
Open Access
Small molecules targeting immune checkpoint proteins for cancer immunotherapy: a patent and literature review (2020-2024)
Qiaohong Geng, Juanjuan Xu, Cheng Du, et al.
Expert Opinion on Therapeutic Patents (2025)
Closed Access
Progress in small-molecule inhibitors targeting PD-L1
J. Xu, Yuanfang Kong, Pengbo Zhu, et al.
RSC Medicinal Chemistry (2024) Vol. 15, Iss. 4, pp. 1161-1175
Closed Access | Times Cited: 4
Computational Approaches Drive Developments in Immune-Oncology Therapies for PD-1/PD-L1 Immune Checkpoint Inhibitors
Patrícia Sobral, Vanessa C. C. Luz, João M. G. C. F. Almeida, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 6, pp. 5908-5908
Open Access | Times Cited: 10
Construction of Hierarchically Biomimetic Iron Oxide Nanosystems for Macrophage Repolarization-Promoted Immune Checkpoint Blockade of Cancer Immunotherapy
Yaqing Kang, Jiao Yan, Xiaoqing Han, et al.
ACS Applied Materials & Interfaces (2024) Vol. 16, Iss. 28, pp. 36131-36141
Closed Access | Times Cited: 3
Discovery of benzo[d]isothiazole derivatives as novel scaffold inhibitors targeting the programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) interaction through “ring fusion” strategy
Yinli Gao, Hanxun Wang, Lanlan Shen, et al.
Bioorganic Chemistry (2022) Vol. 123, pp. 105769-105769
Closed Access | Times Cited: 11
Synthesis and preliminary evaluation of aminophenol derivatives as molecular glues blocking PD-1/PD-L1 interaction
Qiaohong Geng, Yanyan Dong, Jin Peng, et al.
Journal of Molecular Structure (2023) Vol. 1289, pp. 135900-135900
Closed Access | Times Cited: 5
Synthesis and evaluation of indole-containing derivatives as C-linked PD-L1 inhibitors for cancer immunotherapy
Qiaohong Geng, Yanyan Dong, Peng Jin, et al.
Journal of Molecular Structure (2023) Vol. 1294, pp. 136487-136487
Closed Access | Times Cited: 4
Current Medicinal Insights on Synthetic Small Molecules and Natural Origin Products as PD-1/PD-L1 Inhibitors
Shivanshu Pandey, Balak Das Kurmi, Preeti Patel
Current Topics in Medicinal Chemistry (2023) Vol. 23, Iss. 18, pp. 1765-1781
Closed Access | Times Cited: 2
Antioxidant Properties and Aldehyde Reactivity of PD-L1 Targeted Aryl-Pyrazolone Anticancer Agents
Natascha Leleu‐Chavain, Romain Regnault, Hania Ahouari, et al.
Molecules (2022) Vol. 27, Iss. 10, pp. 3316-3316
Open Access | Times Cited: 4
Design of Biphenyl‐Type Programmed Cell Death‐Ligand 1 Inhibitors Using 3D‐QSAR, Molecular Docking, and Molecular Dynamics Simulation
Pengbo Zhu, Jindan Xu, Mingyan Du, et al.
ChemistrySelect (2024) Vol. 9, Iss. 21
Closed Access
Beyond peptides: Unveiling the design strategies, structure activity correlations and protein-ligand interactions of small molecule inhibitors against pd-1/pd-l1
Pujan Sasmal, P. Prabitha, B. R. Prashantha Kumar, et al.
Bioorganic Chemistry (2024) Vol. 154, pp. 108036-108036
Closed Access
Progress in programmed cell death-1/programmed cell death-ligand 1 pathway inhibitors and binding mode analysis
Xiaoyun Li, Qin Zeng, Fengjiao Xu, et al.
Molecular Diversity (2022) Vol. 27, Iss. 4, pp. 1935-1955
Closed Access | Times Cited: 2
In silico Identification of Novel SphK1 Inhibitors
Jin Liu, Hui-Lin Zhao, Lei He, et al.
Letters in Drug Design & Discovery (2023) Vol. 21, Iss. 10, pp. 1886-1893
Closed Access
Virtual screening of drugs targeting PD-L1 protein
Kai-Dong Lin, Xiaoqian Lin, Xubo Lin
Acta Physica Sinica (2023) Vol. 72, Iss. 24, pp. 240501-240501
Open Access
Page 1

Scroll to top